Derma Norte del Bajío, S.C.

Aguascalientes 20130

0 studies enrolling now · 3 studies all time

What they study most

Alopecia Areata, Atopic Dermatitis

Studies at this site

• A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata — Completed
• Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis — Completed
• A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis — Stopped early